Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 32Carcinoma, Non-Small-Cell Lung 29Neoplasms 26Head and Neck Neoplasms 26Colonic Neoplasms 20Neoplasm Metastasis 17Rectal Neoplasms 12Breast Neoplasms 11Lung Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Squamous Cell 6Tongue Neoplasms 5Salivary Gland Neoplasms 5Melanoma 5Stomach Neoplasms 4Solid Tumors 4Ovarian Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumor 4Triple Negative Breast Neoplasms 3Sarcoma 3Kidney Neoplasms 3Endometrial Neoplasms 3Advanced Cancers 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Recurrence 2Pharyngeal Neoplasms 2Neoplasms by Site 2

Interventions

sapanisertib 2MLN 8237 2tovorafenib 1serabelisib 1pevonedistat 1TAK 733 1Paclitaxel 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Nonhematologic Malignancies × Cetuximab × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡